Endocrinology
3 drugs are in development for Hypoparathyroidism.
- Companies
- 3
- Clinical trials
- 13
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Hypoparathyroidism pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| canvuparatide | MBX Biosciences, Inc. (MBX) |
Phase 2(1)
| Drug | Company |
|---|---|
| eb612 | Entera Bio Ltd. (ENTX) |
Preclinical(1)
| Drug | Company |
|---|---|
| pth1r agonist | Septerna, Inc. (SEPN) |
About this indication
Hypoparathyroidism context
Endocrinology·MeSH: Hypoparathyroidism (D007011)
Frequently asked questions
How many drugs are in development for Hypoparathyroidism?
BioSniper tracks 3 drugs in development for Hypoparathyroidism across 3 companies.
How many clinical trials target Hypoparathyroidism?
There are 13 clinical trials targeting Hypoparathyroidism tracked by BioSniper.